# Reporting checklist for randomised trial.

Based on the CONSORT guidelines.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | Reporting Item | Page Number |
| **Title and Abstract** |  |  |  |
| Title | [#1a](https://www.goodreports.org/reporting-checklists/consort/info/#1a) | Identification as a randomized trial in the title. | 1 |
| Abstract | [#1b](https://www.goodreports.org/reporting-checklists/consort/info/#1b) | Structured summary of trial design, methods, results, and conclusions | 2 |
| **Introduction** |  |  |  |
| Background and objectives | [#2a](https://www.goodreports.org/reporting-checklists/consort/info/#2a) | Scientific background and explanation of rationale | 4 |
| Background and objectives | [#2b](https://www.goodreports.org/reporting-checklists/consort/info/#2b) | Specific objectives or hypothesis | 4 |
| **Methods** |  |  |  |
| Trial design | [#3a](https://www.goodreports.org/reporting-checklists/consort/info/#3a) | Description of trial design (such as parallel, factorial) including allocation ratio. | 6 |
| Trial design | [#3b](https://www.goodreports.org/reporting-checklists/consort/info/#3b) | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | 6 |
| Participants | [#4a](https://www.goodreports.org/reporting-checklists/consort/info/#4a) | Eligibility criteria for participants | 7 |
| Participants | [#4b](https://www.goodreports.org/reporting-checklists/consort/info/#4b) | Settings and locations where the data were collected | 7 |
| Interventions | [#5](https://www.goodreports.org/reporting-checklists/consort/info/#5) | The experimental and control interventions for each group with sufficient details to allow replication, including how and when they were actually administered | 7 |
| Outcomes | [#6a](https://www.goodreports.org/reporting-checklists/consort/info/#6a) | Completely defined prespecified primary and secondary outcome measures, including how and when they were assessed | 8 |
| Outcomes | [#6b](https://www.goodreports.org/reporting-checklists/consort/info/#6b) | Any changes to trial outcomes after the trial commenced, with reasons n/a |  |
| Sample size | [#7a](https://www.goodreports.org/reporting-checklists/consort/info/#7a) | How sample size was determined. n/a |  |
| Sample size | [#7b](https://www.goodreports.org/reporting-checklists/consort/info/#7b) | When applicable, explanation of any interim analyses and stopping guidelines n/a |  |
| Randomization - Sequence generation | [#8a](https://www.goodreports.org/reporting-checklists/consort/info/#8a) | Method used to generate the random allocation sequence. 8 |
|  |  |
| Randomization - Sequence generation | [#8b](https://www.goodreports.org/reporting-checklists/consort/info/#8b) | Type of randomization; details of any restriction (such as blocking and block size) 8 |
|  |  |
| Randomization - Allocation concealment mechanism | [#9](https://www.goodreports.org/reporting-checklists/consort/info/#9) | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned n/a |  |
| Randomization - Implementation | [#10](https://www.goodreports.org/reporting-checklists/consort/info/#10) | Who generated the allocation sequence, who enrolled participants, and who assigned participants to interventions 8 |  |
| Blinding | [#11a](https://www.goodreports.org/reporting-checklists/consort/info/#11a) | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how. n/a |  |
| Blinding | [#11b](https://www.goodreports.org/reporting-checklists/consort/info/#11b) | If relevant, description of the similarity of interventions n/a |  |
| Statistical methods | [#12a](https://www.goodreports.org/reporting-checklists/consort/info/#12a) | Statistical methods used to compare groups for primary and secondary outcomes 9 |  |
| Statistical methods | [#12b](https://www.goodreports.org/reporting-checklists/consort/info/#12b) | Methods for additional analyses, such as subgroup analyses and adjusted analyses 9 |  |
| **Results** |  |  |  |
| Participant flow diagram (strongly recommended) | [#13a](https://www.goodreports.org/reporting-checklists/consort/info/#13a) | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome Fig1 |  |
| Participant flow | [#13b](https://www.goodreports.org/reporting-checklists/consort/info/#13b) | For each group, losses and exclusions after randomization, together with reason Fig1 |  |
| Recruitment | [#14a](https://www.goodreports.org/reporting-checklists/consort/info/#14a) | Dates defining the periods of recruitment and follow-up 6 |  |
| Recruitment | [#14b](https://www.goodreports.org/reporting-checklists/consort/info/#14b) | Why the trial ended or was stopped n/a |  |
| Baseline data | [#15](https://www.goodreports.org/reporting-checklists/consort/info/#15) | A table showing baseline demographic and clinical characteristics for each group Table-1 |  |
| Numbers analysed | [#16](https://www.goodreports.org/reporting-checklists/consort/info/#16) | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups 8 |  |
| Outcomes and estimation | [#17a](https://www.goodreports.org/reporting-checklists/consort/info/#17a) | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) 15,16 |  |
| Outcomes and estimation | [#17b](https://www.goodreports.org/reporting-checklists/consort/info/#17b) | For binary outcomes, presentation of both absolute and relative effect sizes is recommended n/a |  |
| Ancillary analyses | [#18](https://www.goodreports.org/reporting-checklists/consort/info/#18) | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory 16 |  |
| Harms | [#19](https://www.goodreports.org/reporting-checklists/consort/info/#19) | All important harms or unintended effects in each group (For specific guidance see CONSORT for harms) n/a |  |
| **Discussion** |  |  |  |
| Limitations | [#20](https://www.goodreports.org/reporting-checklists/consort/info/#20) | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 23 |  |
| Generalisability | [#21](https://www.goodreports.org/reporting-checklists/consort/info/#21) | Generalisability (external validity, applicability) of the trial findings 23 |  |
| Interpretation | [#22](https://www.goodreports.org/reporting-checklists/consort/info/#22) | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 23 |  |
| Registration | [#23](https://www.goodreports.org/reporting-checklists/consort/info/#23) | Registration number and name of trial registry 6 |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
| Protocol | [#24](https://www.goodreports.org/reporting-checklists/consort/info/#24) | Where the full trial protocol can be accessed, if available yes, supplementary |  |
| Funding | [#25](https://www.goodreports.org/reporting-checklists/consort/info/#25) | Sources of funding and other support (such as supply of drugs), role of funders yes |  |